Novavax Inc. (NVAX) 6.49 $NVAX 23.4% Return Seen to Date

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Novavax Inc. (NVAX) 6.49 $NVAX

23.4% Return Seen to Date on SmarTrend Novavax Call (NVAX)
Comtex SmarTrend(R) - Thu Jun 09, 1:55PM CDT
SmarTrend identified an Uptrend for Novavax (NASDAQ:NVAX) on May 24th, 2016 at $5.45. In approximately 2 weeks, Novavax has returned 23.42% as of today's recent price of $6.72.
NVAX: 6.49 (-0.12)

Novavax Announces New Seasonal Combination Respiratory Vaccine Program
Globe Newswire - Thu Jun 02, 3:11PM CDT
- Seasonal influenza nanoparticle approach replaces VLP program
NVAX: 6.49 (-0.12)

Novavax Rises 6.66% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Tue May 31, 5:08PM CDT
Novavax (NASDAQ:NVAX) traded in a range yesterday that spanned from a low of $5.93 to a high of $6.29. Yesterday, the shares gained 6.7%, which took the trading range above the 3-day high of $6.06 on volume of 4.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
NVAX: 6.49 (-0.12)

U.S. FDA Grants Fast Track Designation to Novavax' RSV F Vaccine for Older Adults
Globe Newswire - Wed May 25, 7:01AM CDT
GAITHERSBURG, Md., May 25, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to Novavax' RSV F-Protein nanoparticle vaccine candidate (RSV F Vaccine) for the protection of older adults (60 years of age and older).
NVAX: 6.49 (-0.12)

After Yesterday's Rally of 2.48% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon May 23, 4:22PM CDT
Novavax (NASDAQ:NVAX) traded in a range yesterday that spanned from a low of $5.26 to a high of $5.47. Yesterday, the shares gained 2.5%, which took the trading range above the 3-day high of $5.31 on volume of 2.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
NVAX: 6.49 (-0.12)

Novavax Has Returned 23.9% Since SmarTrend Recommendation (NVAX)
Comtex SmarTrend(R) - Wed May 18, 1:01PM CDT
SmarTrend identified a Downtrend for Novavax (NASDAQ:NVAX) on January 11th, 2016 at $6.74. In approximately 4 months, Novavax has returned 23.88% as of today's recent price of $5.13.
NVAX: 6.49 (-0.12)

Novavax Receives the Tech Council of Maryland's Chairman's Award
Globe Newswire - Thu May 12, 7:30AM CDT
GAITHERSBURG, Md., May 12, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced it received the Tech Council of Maryland's (TCM) Chairman's Award. The award was announced at the TCM Industry Award Celebration on May 11, 2016.
NVAX: 6.49 (-0.12)

Novavax to Participate in the 2016 Citi Midwest Healthcare Access Day
Globe Newswire - Wed May 11, 3:05PM CDT
GAITHERSBURG, Md., May 11, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced management will participate in the 2016 Citi Midwest Healthcare Access Day.
NVAX: 6.49 (-0.12)

Novavax reports 1Q loss
Automated Insights - Wed May 04, 5:30PM CDT
GAITHERSBURG, Md. (AP) _ Novavax Inc. (NVAX) on Wednesday reported a loss of $77.3 million in its first quarter.
NVAX: 6.49 (-0.12)

Novavax Reports First Quarter 2016 Financial Results
GlobeNewswire - Wed May 04, 3:05PM CDT
Novavax, Inc., (Nasdaq:NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced its financial results for the first quarter ended March 31, 2016.
NVAX: 6.49 (-0.12)

Better Buy: Inovio Pharmaceuticals Inc. vs. Novavax Inc.
Keith Speights, The Motley Fool - Motley Fool - Tue May 03, 2:25PM CDT
Image Source: Inovio Pharmaceuticals Similarities only go so far. Inovio Pharmaceuticals and Novavax illustrate the point. Both are clinical-stage biotechs with hopes to win regulatory approval for vaccines in the relatively near future. Both...
INO: 10.62 (-0.39), NVAX: 6.49 (-0.12)

Novavax to Host Conference Call to Discuss First Quarter Financial Results on May 4, 2016
Globe Newswire - Wed Apr 27, 3:09PM CDT
GAITHERSBURG, Md., April 27, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced it will report its first quarter 2016 financial and operating results after the close of U.S. financial markets on Wednesday, May 4, 2016.
NVAX: 6.49 (-0.12)

Novavax to Participate in the FBR New Prescriptions Conference
Globe Newswire - Wed Apr 13, 3:06PM CDT
GAITHERSBURG, Md., April 13, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced Stanley C. Erck, President and Chief Executive Officer, will participate in a panel discussion at the FBR Healthcare Series Conference New Prescriptions: Innovation in the Treatment of Diseases and Infections.
NVAX: 6.49 (-0.12)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Michaels' Countdown to Craftsmas: Screen-Free Holiday Offer

Updated Category News Views 90

Crafting Memories over Clicking Screens The holidays are supposed to be about making memories, right? Well, Michaels is banking on that idea by pulling people away from their screens and nudging them into a hands-on world with its "Countdown to Craftsmas" advent calendar. Starting November 27, they’re tossing in a freebie that’s packing some crafty punches — just...

Continue Reading
Abbisko's PIMJETMI® Gains FDA Nod, Boosting TGCT Treatment

Updated Category News Views 89

PIMJETMI® Scores FDA Approval, Expanding Global Reach Well, here's something to chew on over your morning coffee—PIMJETMI® (pimicotinib) just snagged the U.S. FDA's blessing to treat tenosynovial giant cell tumor (TGCT), making it another notch on Abbisko Therapeutics' belt. This approval is a strategic home run for Abbisko and their pals at Merck KGaA, Darmstadt,...

Continue Reading
Cepheid Expands Diagnostic Potential with IVDR Approval

Updated Category News Views 106

A Key Milestone for Cepheid Breathing new life into Europe's diagnostic landscape, Cepheid's Xpert Respiratory Panel just snagged the CE marking under the IVDR. This ain't just some technical checkbox; this test's got the goods to spot 13 respiratory pathogens from one measly swab. It's a hefty lineup—think Adenovirus, different flavors of flu, and even the sneaky...

Continue Reading
Supermetrics Debuts AI Campaign Manager for Marketers

Updated Category News Views 88

These days, digital marketing feels like trying to build a puzzle in a sandstorm. You've got all these pieces flying around, valuable insights buried somewhere in the mix, and you can't just toss 'em together however you like. Supermetrics steps into this whirlwind with their new tool, Campaign Manager, promising marketers a direct line from insight to action. Finally, a...

Continue Reading
The DOG CATCHER: A New Spin on Pet Waste Cleanup

Updated Category News Views 43

Revolutionizing the Dreaded Pet Waste Duty Folks, here's a little dose of innovation from the streets of Baltimore: a gadget called the DOG CATCHER. No, it’s not about catching stray dogs, but dealing with their unpleasant leavings. This invention's got a patent pending and all, promising to make the nasty business of dog waste collection a whole lot less disgusting. I...

Continue Reading
Bybit Enhances Copy Trading with Fine-Tuned Filters

Updated Category News Views 70

Fine-tuning in the Wild West of Copy Trading Pull up a chair, because this is one for the books. Bybit, that sprawling new financial playground trusted by 80 million folks around the globe, just laid another stone on the path to trading enlightenment with their Copy Trading Classic. They’ve cranked up the ability to sift through Master Traders like a prospector panning...

Continue Reading
Alyssa Bunch: Big Moves in Tennessee Real Estate

Updated Category News Views 104

Navigating the Tennessee Real Estate Maze If you're talking about where the real estate action happens in Tennessee, you'd better mention Alyssa Bunch, the Vanderbilt-educated dynamo who turns the unforsale into the must-buy. Most of the deals she orchestrates are invisible to the public eye until they're all but written in ink and ready to reshape landscapes—or, more...

Continue Reading
Braemar's $358 Million Refinance: A Strategic Shift

Updated Category News Views 62

Reworking the Debt Load: Braemar's New Move Most days, when a company decides to tinker with its debt, it's like watching paint dry for investors. But with Braemar Hotels & Resorts (NYSE: BHR) announcing a $358 million refinancing package, they're bringing a fresh breath of air to the table. Lemme walk you through why this matters beyond the glossy façade of luxury hotel...

Continue Reading
Centrus Energy Welcomes Nuclear Veteran to Leadership

Updated Category News Views 71

Navigating a New Era at Centrus When you hear about seasoned veterans stepping up to the plate in the energy sector, it's time to perk up your ears. Centrus Energy (NYSE:LEU), a big player in nuclear fuel, just added Kevin Graney to their Board of Directors. This isn't your run-of-the-mill appointment; it packs nearly three decades of nuclear tech and national security...

Continue Reading
Retail's AI Ambitions Clash with In-Store Data Realities

Updated Category News Views 127

AI's Lofty Goals Meet Retail's Messy Reality I swear, all this chatter about AI transforming retail sounds grand until you dig into the messy trenches, right? This latest Scandit survey lays it bare: retailers have got their AI visions sprinting ahead of the stock data realities inside their stores. Seems those shiny new systems rely on stock data that matches what's...

Continue Reading

Top 5 Most Recently Viewed Articles

Rivian's Strategic Expansion with Volkswagen Boosts EV Journey

Updated Category News Views 300

Rivian and Volkswagen Strengthen Their Collaboration Recent discussions between Volkswagen and Rivian highlight the potential for an expanded partnership that may greatly impact the electric vehicle (EV) industry. Volkswagen’s CEO, Oliver Blume, recently commented on the exciting opportunities presented by this collaboration, which focuses on leveraging shared resources...

Continue Reading
Investigation Announced for TransMedics Group, Inc. Investors

Updated Category News Views 199

Investigation into TransMedics Group, Inc. Announced The Rosen Law Firm, a prominent legal practice dedicated to defending investor rights, has recently initiated an investigation regarding potential securities claims on behalf of shareholders of TransMedics Group, Inc. (NASDAQ: TMDX). This move follows serious allegations that the company may have provided materially...

Continue Reading
Significant Regulatory Challenges for Telix Pharmaceuticals Unfold

Updated Category News Views 145

Regulatory Challenges for Telix Pharmaceuticals Telix Pharmaceuticals Ltd. (NASDAQ: TLX) is currently navigating through difficult regulatory waters, prompting investors to rethink their positions. A recent reminder issued by the well-regarded national law firm Hagens Berman highlights the mounting issues surrounding the company's prostate cancer drug, TLX591, and its...

Continue Reading
Invest Green Acquisition Corp Secures $172.5 Million IPO Success

Updated Category News Views 233

Invest Green Acquisition Corporation Celebrates IPO Achievement Invest Green Acquisition Corporation is thrilled to announce the successful closing of its initial public offering, which raised an impressive $172.5 million. This achievement represents the sale of 17,250,000 units at a price of $10.00 per unit. The offering included the exercise of an overallotment option...

Continue Reading
Anticipated Growth in Automotive Suspension Market by 2034

Updated Category News Views 135

Significant Growth Anticipated in the Automotive Suspension Sector The global automotive suspension shock absorber market is forecasted to grow remarkably from USD 31.5 billion to USD 45.2 billion over the next decade, with an average annual growth rate of 4.0%. This surge reflects evolving consumer priorities towards enhanced comfort, safety, and advanced vehicle...

Continue Reading